Stelara (also known by its generic name ustekinumab) was approved by the FDA in September 2009 for the treatment of moderate-to-severe plaque psoriasis in patients ages 6 years and older. Stelara is also approved to treat patients 6 years and older with active psoriatic arthritis.
Stelara is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterward.
To learn more, please visit the Stelara website.
Biosimilars for Stelara
A biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits, and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.